0001193125-22-244714.txt : 20220914 0001193125-22-244714.hdr.sgml : 20220914 20220914160154 ACCESSION NUMBER: 0001193125-22-244714 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220914 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220914 DATE AS OF CHANGE: 20220914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37695 FILM NUMBER: 221243012 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-409-5300 MAIL ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140813 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 8-K 1 d333214d8k.htm 8-K 8-K
NASDAQ false 0001445283 0001445283 2022-09-14 2022-09-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 14, 2022

 

 

YUMANITY THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-37695   20-8436652

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

40 Guest Street, Suite 4410

Boston, MA

   02135
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 409-5300

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☒

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol

  

Name of exchange

on which registered

Common Stock, par value $0.001 per share   YMTX   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01

Regulation FD Disclosure.

As previously disclosed, on June 5, 2022, Yumanity Therapeutics, Inc., a Delaware corporation (“Yumanity”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceutica NV (“Janssen”). Concurrently with the execution of the Asset Purchase Agreement, on June 5, 2022, Yumanity entered into an Agreement and Plan of Merger with Kineta, Inc., a Washington corporation (“Kineta”), and Yacht Merger Sub, Inc., a Washington corporation and wholly-owned subsidiary of Yumanity.

On September 14, 2022, Kineta issued a press release announcing that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Virtual Symposium, to be held as a virtual event on September 23, 2022. The press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Important Information and Where to Find It

This communication may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen. In connection with the proposed transactions, on August 29, 2022, Yumanity filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), which contains a preliminary proxy statement and prospectus. The Registration Statement has not yet become effective. Yumanity will mail the definitive proxy statement/prospectus to the Yumanity securityholders, and the securities may not be sold or exchanged until the Registration Statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions. This communication is not a substitute for the Registration Statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.

Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Participants in the Solicitation

Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the preliminary proxy statement/prospectus

included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus and any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K and the exhibit furnished herewith contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; the listing of the combined company on Nasdaq after the closing of the proposed merger; expectations regarding the ownership structure of the combined company after the closing of the proposed merger; the expected executive officers and directors of the combined company; the expected cash position of each of Yumanity and Kineta and the combined company at the closing of the proposed merger; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; the executive and board structure of the combined company; the location of the combined company’s corporate headquarters; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; Kineta having sufficient resources to advance its pipeline; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the risk that the conditions to the closing of the proposed transactions are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Yumanity, Kineta and Janssen to consummate the proposed merger or asset sale, as applicable; (iii) risks related to Yumanity’s ability to manage its operating expenses and its expenses associated with the proposed transactions pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) the risk that as a result of adjustments to the exchange ratio, Yumanity stockholders and Kineta shareholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Yumanity’s common stock relative to the exchange ratio; (vii) unexpected costs, charges or expenses resulting from either or both of the proposed transactions; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transactions; (ix) the risk that the amount of the dividend distributed to Yumanity stockholders in connection with the asset sale, if any, may be lower than currently anticipated; (x) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (xi) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xiii) risks associated with the possible failure to realize certain anticipated benefits of the proposed transactions, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Yumanity’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC, and in other filings that Yumanity makes and will make with the SEC in connection with the proposed transactions, including the proxy statement/prospectus described under “Important Information and Where to Find It.” You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Except as required by law, Yumanity expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

   

Description

99.1    Press release, dated September 14, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 14, 2022   Yumanity Therapeutics, Inc.
    By:  

/s/ Richard Peters

    Name:   Richard Peters
    Title:   President & Chief Executive Officer
 EX-99.1 2 d333214dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium

Seattle, WA — (September 14, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Symposium. The virtual event will take place on September 23, 2022.

“I am excited to join leading immuno-oncology experts in discussing the latest advances in anti-VISTA immunotherapies,” said Dr. Guillaudeux. “VISTA is an important myeloid checkpoint with a unique mechanism of action bridging innate and adaptive immunity. Anti-VISTA therapies have great potential to improve cancer treatment outcomes in a variety of solid tumors, especially for patients resistant to standard of care therapies including first generation immune checkpoint inhibitors.”

Dr. Guillaudeux will join leading researchers and clinicians in immunology to discuss new insights into VISTA, a promising therapeutic target for cancer. The symposium will focus on VISTA’s function and applicability in cancer immunology, as well as the latest research and development in programs targeting VISTA.

Presentation Details:

Session Title: VISTA Biology

Date: September 23, 2022

Time: 9:20 AM to 10:00 AM Eastern Time

Session Title: Anti-VISTA Therapeutic Strategies

Date: September 23, 2022

Time: 12:10 PM to 12:55 PM Eastern Time

Click on the link below for additional details and to register for the symposium:

https://www.eventbrite.com/e/2nd-annual-vista-symposium-tickets-374510088757

####

Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

LOGO

 

PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways. It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND-enabling and clinical studies.

KVA12.1 is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.

Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.

Additional Information and Where to Find It

This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity Therapeutics, Inc. (“Yumanity”) and Kineta and between Yumanity and Janssen Pharmaceutica NV (“Janssen”). In connection with the proposed transactions, Yumanity filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 29, 2022 a registration statement on Form S-4 (“the Registration Statement”), which contains a preliminary proxy statement and prospectus. The Registration Statement has not yet become effective. Yumanity will mail the definitive proxy statement/prospectus to the Yumanity securityholders, and the securities may not be sold or exchanged until the Registration Statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions. This press release is not a substitute for the Registration Statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.

Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

LOGO

 

Participants in the Solicitation

Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the preliminary proxy statement/prospectus included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus and any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects; statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including, without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:

Jacques Bouchy

jbouchy@kineta.us

(206) 378-0400

Source: Kineta, Inc.

EX-101.SCH 3 ymtx-20220914.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ymtx-20220914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ymtx-20220914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g333214snap0041.jpg GRAPHIC begin 644 g333214snap0041.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( #4 QP,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@"*ZNH+*UDN;F58H(EW.[' 44TFW9";25V>1:W\5/$&K7[ M:=X'T9IV''GR1EV/N%Z*/=C6\Z#A&[9C&LI.R.M=O&__ JY60+_ ,)=L!(Q M'C=YG(_N_NWD,/=3^%)2MN M.W8]GLKVVU&RAO+*=)[:90\C MAE&E!U9'%7;G-4T;NHSP>"-#^P:#9QF95RSN. ?[S>I->=6K2D[L]K+\#"H[ M2=E^96O?$>L6_P )#KJ3@ZH%!#B,$$F7;C;TZ<5,7=7-IX>G'&.C]G_@%JUT MFX\>>"!;>,])B@GE&5"'YTXX<9^XWMGZ^E-JZ..O&G"I:F[HX'X5ZC?^#/'N MH_#[5)2\)9GM6/3!?BBVN^$]8U[7XK:R@TZ0*3#NY&T'N3DDG %2I: T9 M_@3XF>*?'?B.2"UT>RM](@;=-.^\LB?PKUP7/^)H3;&TD>FZU?2:9H.H7\2J M\EK;23*K="54D _E5/1$HX7X4_$74O'IU0:A9VUM]C$>SR-W.[=G.2?[M3&5 MV4U8U?B9XPO/!'AB+5+&V@GE>Y6$K-G;@ACG@CTIR=A)7,WX9?%"/QPD]G?1 M16FK0_/Y49.V2/U7/.1W'THC*X-6,WXB?%/5?!WC"TT:RL;2>&:&.0O-NW L MY4]#[4G*S&E<]7JR3P74/CAXHA\1W^E6&A6=TUO<21(J)(SLJL1G /H*SYF5 M9'HOPX\5ZYXKTV]N-3FWM?#MG/,H),<4 N(IUL[>VN)))VM9)9Y+5K<6IBE+N#E% M#D] >6^8@G S5"/7Z "@#Q3P#-]I^._BH7'^MB\_9G_KHH_E6CK7AR$*G:7, M9WBCQ;/%KVL6DK8VW+I@^@.!^F*Y))MGV>$I4E1A+R/4_A\R77@'29&4,"K, M 1W#MBM8JRL?.X^5\5-H\YU;Q5XHNOBKI&GWL$FGV\-Z@CM5.0ZDXW$C[V03 M["GU.VG0HQPTI1U=MQGQ M_V@?"-(:[W/M'RF8(, _P# >GXUCJ6?57PQ M'A\>!;#_ (1S_CUQ^\W8\SS?XM_^UG],8XQ6L;6(9L>+/^1.US_KQG_]%FF] M@6YX]^SA][Q#](/_ &>HAN5(Z3]H#_DGMO\ ]?\ '_Z"].8HGC\?AS5O#OA3 M0?'^BS./G;SB/^6+AV4$^J,!@_\ UZBUM2O(7QWXLM_&GBK1=6@0Q2?9H8YX MC_!()&R!ZCD$?6ANX)6/K2MC,^2K.[\067Q7U2?PQ;^?J@N[D(FP-E=S;N#[ M5CK?0OH?0OPZO_%FH:)+[7[->K<%8U\L)F/:.< ^N:TC?J2[=#L*H1\V_ M!3_DK6I?]<+C_P!&+64=RWL?25:D'S'\1]7MO%WQ?@T^XNXX-+LI5M&ED8*B M@',K9^N1^ K)N[+6B(_#.K6'@OXV,-.NX9M&N)S;B2)PR>5)@KR/[I*_D:2= MF#V/J"MB H * /!?&AF^''QGM/%8B8Z7J7$VT>H"R#Z\!QZUF]'O&,CKQ5[['JX+%Q@O9U/D;FGS:MHWP/M9 M;"*:+5+=!LC\HE\^=T*XST[4+8RFH5,8U+;_ (!U6A";7M,T[4]?T1+/4X"6 M17P60XQN'=7Q#JT"C3+2,/:2(V5; VJOL MP)9C46UN8WT/6*LDY_QQI=WK?@C5],L8Q)=7-N4C4L%!/U/2D]AHX'X>?#*[ MM?!>N:#XKLD1+Z8,@217*X4 ,".A!J5'2S&V97@3P5X^\ >*I?(M(KW19I-D MX6X1?,3/$@4GA@.WU%))H;:9[%X@M)K_ ,-ZI9VZAI[BUEBC!.,LR$#GZFK> MQ"/./@OX(U[P<=8_MNU2#[2(O+VRJ^=N[/0\=14Q5F4V;?Q<\,:KXL\(0Z?H M\"S7*W:2E6D"#:%8'D_4425Q)V+?@'PQ/I?PVM/#^O6D9?9*D\)8.I5G8XR. M.AII:6![GCVK? [Q)8^)V_L6".ZTI9E>*1YU5@N<[2">HZ9[U'*RKH^DZU(/ MG*?X;?$;3_&>H:WH=NEO))*_#+X>>)?#7Q!O-6U2SCBLY8IE5U MF5B2S@C@'/05G%-,IL]>U9[V/2+M]-A$U\(F\B,L%#/CY&^"_@= M=W=W?3^-HGC4@&)8+@%GY;?8?XW^!30I9R>#(9)&RPN$GN " M.FU@3CW_ $H<>PDSVCPZ=2/AW3QK$(BU%856X4.&&\#!.1QSC/XU:V)-.F 4 M 9/B3PWIOBK19M*U2'?!)R&'#1L.C*>Q%)JX+0\8BT/XD_"JXD30P=;T,L6$ M00N!]4!W*?\ =XJ+.)6C+?\ PO/Q!M\G_A")OM73&Z3&?]W9FCF8 XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Sep. 14, 2022
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001445283
Document Type 8-K
Document Period End Date Sep. 14, 2022
Entity Registrant Name YUMANITY THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37695
Entity Tax Identification Number 20-8436652
Entity Address, Address Line One 40 Guest Street
Entity Address, Address Line Two Suite 4410
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02135
City Area Code (617)
Local Phone Number 409-5300
Written Communications true
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol YMTX
Entity Emerging Growth Company false
XML 8 d333214d8k_htm.xml IDEA: XBRL DOCUMENT 0001445283 2022-09-14 2022-09-14 NASDAQ false 0001445283 8-K 2022-09-14 YUMANITY THERAPEUTICS, INC. DE 001-37695 20-8436652 40 Guest Street Suite 4410 Boston MA 02135 (617) 409-5300 true false false false Common Stock, par value $0.001 per share YMTX false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d333214d8k.htm 7 d333214d8k.htm d333214dex991.htm ymtx-20220914.xsd ymtx-20220914_lab.xml ymtx-20220914_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d333214d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d333214d8k.htm" ] }, "labelLink": { "local": [ "ymtx-20220914_lab.xml" ] }, "presentationLink": { "local": [ "ymtx-20220914_pre.xml" ] }, "schema": { "local": [ "ymtx-20220914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ymtx", "nsuri": "http://yumanity.com/20220914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d333214d8k.htm", "contextRef": "duration_2022-09-14_to_2022-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d333214d8k.htm", "contextRef": "duration_2022-09-14_to_2022-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://yumanity.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-244714-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-244714-xbrl.zip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end